Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
Significant news last week included Vertex Pharmaceuticals dropping development of its acute pain candidate VX-993 following a Phase II trial miss. Health and Human Services (HHS) Secretary Robert F Kennedy Jr continued his vaccine skepticism, announcing a wind-down in funding for mRNA vaccines. USA-based Eledon Pharmaceuticals released encouraging early trial results on its tegoprubart in renal transplantation. Also, US pharma major Eli Lilly reported new data on its investigational obesity drug orforglipron that failed to show a benefit over a rival candidate from Novo Nordisk. 10 August 2025
Related News
Insights
Company Spotlight
Skyhawk is developing small molecule therapeutics that correct RNA expression.
Latest News & Features of interest to Vertex Pharmaceuticals
Pharmaceutical
PTC Therapeutics yesterday revealed that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia. 20 August 2025
Biotechnology
The US Food and Drug Administration (FDA) has extended Regenxbio’s review timeline of the Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for the treatment of mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. 20 August 2025
Pharmaceutical
The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. 20 August 2025
Pharmaceutical
Today’s announcement (August 20) on draft guidelines from the UK’s National Institute for Health and Care Excellence (NICE) moves away from a 'one-size-fits-all' approach, shifting from automatically starting everyone on one medicine to personalized treatment plans that aim to prevent heart failure, heart attacks and other serious medical problems. 20 August 2025
Pharmaceutical
GoodRx has teamed up with Novo Nordisk to make all dose levels of Ozempic (semaglutide) and Wegovy (semaglutide) available to eligible self-paying patients for $499 per month. The move marks the first time Ozempic has been offered at this price point. 19 August 2025
Pharmaceutical
The European Commission (EC) granted marketing authorization for Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. 18 August 2025
Pharmaceutical
Australia’s Neurizon Therapeutics saw its shares rise 10% to A$0.16 today. after it revealed that it has been informed by the US Food and Drug Administration (FDA) that the decision on its Clinical Hold Complete Response (CHCR) to the Investigational New Drug (IND) application for NUZ-001, the company’s lead investigational therapy for amyotrophic lateral sclerosis (ALS), is now expected by October 3, 2025. 18 August 2025
Pharmaceutical
Brazil’s Fiocruz, through the Drug Technology Institute (Farmanguinhos), and the pharmaceutical company EMS have signed two unprecedented partnership agreements for the production of liraglutide and semaglutide, during an event in Brasília. 18 August 2025
Pharmaceutical
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
Pharmaceutical
Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug Administration (FDA) has approved an additional indication for the drug. 16 August 2025
Latest In Brief for Vertex Pharmaceuticals
Biosimilars
Hungarian drugmaker Gedeon Richter has announced that the European Commission has granted marketing authorization for the biosimilar denosumab products Junod and Yaxwer. 2 July 2025
Latest Relevant Ones To Watch News
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
12 August 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze